{"id":"NCT01721876","sponsor":"Boehringer Ingelheim","briefTitle":"Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)","officialTitle":"A Phase III Randomised, Double-blind, Controlled, Parallel Group Study of Intravenous Volasertib in Combination With Subcutaneous Low-dose Cytarabine vs. Placebo + Low-dose Cytarabine in Patients >=65 Years With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-01-29","primaryCompletion":"2014-08-12","completion":"2021-05-28","firstPosted":"2012-11-06","resultsPosted":"2021-11-19","lastUpdate":"2023-02-08"},"enrollment":666,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Leukemia, Myeloid, Acute"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Volasertib","otherNames":[]},{"type":"DRUG","name":"Cytarabine","otherNames":[]}],"arms":[{"label":"Volasertib and Cytarabine","type":"EXPERIMENTAL"},{"label":"Placebo and Cytarabine","type":"PLACEBO_COMPARATOR"}],"summary":"To investigate the efficacy, safety, and pharmacokinetics of intravenous volasertib + subcutaneous low dose cytarabine in patients \\>= 65 years of age with previously untreated acute myeloid leukaemia, ineligible for intensive remission induction therapy","primaryOutcome":{"measure":"Objective Response (OR)","timeFrame":"Response assessment was performed at the end of every 2nd cycle, (i.e. at the end of Cycle 2, 4, 6, 8, etc., and at end of treatment), i.e. up to 52 months.","effectByArm":[{"arm":"Placebo + Low-dose Cytarabine","deltaMin":38,"sd":null},{"arm":"Volasertib + Low-dose Cytarabine","deltaMin":123,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0024"}]},"eligibility":{"minAge":"65 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":122,"countries":["United States","Argentina","Austria","Belgium","Brazil","Canada","Czechia","Finland","France","Germany","Greece","Hungary","India","Italy","Japan","Mexico","Netherlands","Norway","Poland","Portugal","Russia","South Africa","South Korea","Spain","Taiwan"]},"refs":{"pmids":["34646387"],"seeAlso":["http://www.mystudywindow.com/"]},"adverseEventsSummary":{"seriousAny":{"events":163,"n":222},"commonTop":["Thrombocytopenia","Nausea","Anaemia","Constipation","Diarrhoea"]}}